Eisai/Pfizer Get U.S. FDA Complete Response For Alzheimer's Patch
This article was originally published in PharmAsia News
Eisai Inc. announced April 25 that FDA has issued a "complete response" for the transdermal patch version of its best-selling drug Aricept (donepezil) for Alzheimer's disease
You may also be interested in...
TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training
After Eisai tried to get out of its co-promotion deal for the Alzheimer’s disease blockbuster, the two companies settle their dispute with Japanese rights to Aricept returning to Eisai sooner than originally planned.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).